DEA Proposal To Schedule Kratom Stirs Wave Of Opposition
This article was originally published in The Rose Sheet
AHPA and the American Botanical Council are among the opponents of DEA's proposal to schedule the active materials in kratom while NPA supports it, saying kratom products and raw ingredients have not met "the strict standards products and new ingredients must adhere to in order to be marketed to the public."
You may also be interested in...
CSPI says FDA has warned companies about tianeptine, which stimulates opioid receptors and may trigger addiction and withdrawal symptoms. But “tianeptine products continue to be widely available in Alabama and online.”
As in previous warnings to kratom supplement marketers linked to opioid addiction treatment claims, FDA tells Cali Botanicals and Kratom NC that HHS in 2017 found opioid abuse was nationwide public health emergency and FDA is targeting products that without approval claim to diagnose, mitigate, prevent, treat or cure opioid addiction. Contract manufacturer Somlabs' GMP problems also were identified in FDA's latest warning letters.
Ohio Board of Pharmacy proposes placing into Schedule I kratom constituent ingredients mitragynine and 7-hydroxymitragynine, a change that would prohibit kratom sales in the state. The board's findings "parrot the false propaganda" of FDA in its "crusade to ban kratom," says the American Kratom Association.